PT  - JOURNAL ARTICLE
AU  - Yusaku Akashi
AU  - Michiko Horie
AU  - Junichi Kiyotaki
AU  - Yuto Takeuchi
AU  - Kenichi Togashi
AU  - Yuki Adachi
AU  - Atsuo Ueda
AU  - Shigeyuki Notake
AU  - Koji Nakamura
AU  - Norihiko Terada
AU  - Yoko Kurihara
AU  - Yoshihiko Kiyasu
AU  - Hiromichi Suzuki
TI  - Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza AB for the Detection of SARS-CoV-2 in Nasal Samples
AID  - 10.1101/2022.01.07.22268874
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.07.22268874
4099  - http://medrxiv.org/content/early/2022/01/10/2022.01.07.22268874.short
4100  - http://medrxiv.org/content/early/2022/01/10/2022.01.07.22268874.full
AB  - Background and Objective Point-of-care type molecular diagnostic tests have been used for detecting SARS-CoV-2, although their clinical utility with nasal samples has yet to be established. This study evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza AB (Liat) in nasal samples.Methods Nasal and nasopharyngeal samples were collected and were tested using the Liat, the cobas 6800 system and the cobas SARS-CoV-2 & Influenza AB (cobas), and a method developed by National Institute of Infectious Diseases, Japan (NIID).Results A total of 814 nasal samples were collected. The Liat assay was positive for SARS-CoV-2 in 113 (13.9%). The total, positive, and negative concordance rate between the Liat and cobas/NIID assays were 99.3%/98.4%, 99.1%/100%, and 99.3%/98.2%, respectively. Five samples were positive only using the Liat assay. Their Ct values ranged from 31.9 to 37.2. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of other molecular assays. In the participants who tested positive for SARS-CoV-2 on the Liat assay using nasopharyngeal samples, 88.2% of their nasal samples also tested positive using the Liat assay.Conclusion The Liat assay showed high concordance with other molecular assays in nasal samples. Some discordance occurred in samples with Ct values > 30 on the Liat assay.Key PointsThe cobas Liat SARS-CoV-2 & Influenza AB assay showed high concordance with other molecular assays in nasal and nasopharyngeal samples, providing results within 20 minutes.Some discordance occurred in samples with Ct values > 30 on the Liat assay.The Liat assay may be suitable for use in a variety of clinical situations, primarily where accurate detection of SARS-CoV-2 is necessary.Competing Interest StatementRoche Diagnostics K.K., provided support in the form of salaries to author Michiko Horie, Kenichi Togashi, and Yuki Adachi. Molecular examinations using Liat, cobas, NIID, and Xpert Xpress were performed with financial support from Roche Diagnostics K.K. Hiromichi Suzuki was awarded lecture fee from Roche Diagnostics K.K.Funding StatementThis study was financially supported by Roche Diagnostics K.K.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed in accordance with the principles of the Declaration of Helsinki and with the STROBE guidelines and was approved by the ethics committee of the University of Tsukuba (approval number: R03-41).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors